Table 2

Respiratory support and medical treatment to pregnant women with symptoms who were admitted to hospital with SARS-CoV-2 infection in the UK between 15 December 2021 and 14 March 2022

No of women% (95% CI)
Total98626.7 (25.3 to 28.1)
Composite indicator of moderate to severe infection14414.6 (12.5 to 17.0)
Oxygen saturation measured on admission (yes)85786.9 (84.7 to 88.9)
Oxygen saturation <95%314.2 (2.9 to 5.9)
Evidence of pneumonia on imaging727.3 (5.8 to 9.1)
Respiratory support required:*9910.4 (8.6 to 12.5)
 Non-invasive oxygen (nasal canulae, mask, or non-rebreathe mask at <15 L/min)7178.9 (69.3 to 86.1)
 High flow nasal oxygen (≥15 L/min) or CPAP77.8 (3.6 to 15.4)
 Invasive ventilation or ECMO1213.3 (6.1 to 27.6)
 Level not known9
Intensive care unit admission303.0 (2.1 to 4.3)
Maternal death40.4 (0.1 to 1.1)
Pharmacological management total:505.1 (3.9 to 6.6)
 Antivirals30.3 (0.1 to 0.9)
 Tocilizumab90.9 (0.5 to 1.8)
 Corticosteroids for maternal indication434.4 (3.2 to 5.8)
 Monoclonal antibodies60.6 (0.3 to 1.4)
 Recruited to RECOVERY trial50.5 (0.2 to 1.2)
  • CPAP=continuous positive airway pressure; ECMO=extracorporeal membrane oxygenation; CI=confidence interval.

  • *Information about need for respiratory support was available for 953 women.

  • †Any of the listed medications given for medical management of SARS-CoV-2: antivirals, tocilizumab, maternal corticosteroids, and monoclonal antibodies.